缩性心力衰竭住院患者功能恶化:患病率和危险因素
Amirhosein Ghafouri Asbagh1, Mohammadreza Taban Sadeghi1, Parisa Ramazanilar1
1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
ESC heart failure
|July 6, 2023
概括
恶化功能 (WRF) 影响了超过三分之一的住院心力衰竭患者. 关键预测因素包括低血和低血红蛋白,强调了早期识别的必要性,以改善结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 经常涉及脏并发症,功能恶化 (WRF) 影响了大量患者.
- 缩性心力衰竭是缩性心力衰竭症状恶化的公认预测因素.
- 了解住院患者的WRF患病率和风险因素对于临床管理至关重要.
研究的目的:
- 确定缩性心力衰竭住院患者功能恶化 (WRF) 的患病率.
- 在这个患者群体中确定与WRF相关的独立风险因素.
主要方法:
- 一项横截面研究分析了347名心力衰竭患者的医疗记录,其中包括心力衰竭患者的心力衰竭和减少喷射率 (HFrEF).
- 患者根据医院内WRF发生情况进行了分类.
- 统计分析,包括多变量分析,使用SPSS版本20.0.0进行.
主要成果:
- 在住院的HFrEF患者中,WRF的患病率为33.71% (347例中117例).
- WRF的独立预测因素包括低血血,血红蛋白度降低,白细胞计数升高和之前使用利尿剂.
- 患有WRF的患者在医院住院时间明显长.
结论:
- 低血症,血红蛋白水平,白细胞计数和先前的利尿剂使用是系统性心力衰竭中WRF的显著独立预测因素.
- 识别这些临床特征有助于识别WRF的高风险患者.
- WRF与心力衰竭患者的死亡率和停留时间增加有关.
相关概念视频
01:22Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16